AstraZeneca/Daiichi Sankyo Line Up More Enhertu Indications
Promising Phase II Data In Multiple Tumor Types
The high-profile antibody-drug conjugate has shown its potential to improve outcomes for heavily pre-treated patients in diseases such as bladder, cervical, pancreatic and rare cancers in a mid-stage trial.
